東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁 到查詢結果 [ subject:"Cells- Aging." ]

切換: 標籤 | MARC模式 | ISBD

Senolytics in disease, ageing and lo...

Munoz-Espin, Daniel.

FindBook

Google Book

Amazon

博客來

Senolytics in disease, ageing and longevity

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Senolytics in disease, ageing and longevity/ edited by Daniel Munoz-Espin, Marco Demaria.
其他作者:	Munoz-Espin, Daniel.
出版者:	Cham :Springer International Publishing : : 2020.,
面頁冊數:	x, 222 p. :ill. (some col.), digital ;24 cm.
內容註:	Part I: Origins and Development of Senotherapies -- Chapter 1. Senolytic drug development -- Chapter 2. Discovery of Senolytics and the pathway to early phase clinical trials -- Part II: The Impact of Senotherapies: from Regeneration to Aging -- Chapter 3. Interconnection between cellular senescence, regeneration and ageing in salamanders -- Chapter 4. Senolytics target senescent cells and improve aging and age-related diseases -- Chapter 5. Senotherapy of cancer -- Part III: Understanding and Targeting the Senescent Surfaceome -- Chapter 6. Targeted senolytic strategies based on the senescent surfaceome -- Chapter 7. Senolysis and senostasis through the plasma membrane -- Part IV: Novel Senescence-Associated Markers and Targets -- Chapter 8. In situ detection of miRNAs in senescent cells in archival material -- Chapter 9. Novel probes and carriers to target senescent cells -- Chapter 10. Potential applications of aptamers for targeting senescent cells -- Chapter 11. Mitochondria: potential targets for interventions to counteract senescence.
Contained By:	Springer eBooks
標題:	Cells - Aging. -
電子資源:	https://doi.org/10.1007/978-3-030-44903-2
ISBN:	9783030449032

Senolytics in disease, ageing and longevity
Senolytics in disease, ageing and longevity[electronic resource] /edited by Daniel Munoz-Espin, Marco Demaria. - Cham :Springer International Publishing :2020. - x, 222 p. :ill. (some col.), digital ;24 cm. - Healthy ageing and longevity,v.112199-9007 ;. - Healthy ageing and longevity ;v.11..

Part I: Origins and Development of Senotherapies -- Chapter 1. Senolytic drug development -- Chapter 2. Discovery of Senolytics and the pathway to early phase clinical trials -- Part II: The Impact of Senotherapies: from Regeneration to Aging -- Chapter 3. Interconnection between cellular senescence, regeneration and ageing in salamanders -- Chapter 4. Senolytics target senescent cells and improve aging and age-related diseases -- Chapter 5. Senotherapy of cancer -- Part III: Understanding and Targeting the Senescent Surfaceome -- Chapter 6. Targeted senolytic strategies based on the senescent surfaceome -- Chapter 7. Senolysis and senostasis through the plasma membrane -- Part IV: Novel Senescence-Associated Markers and Targets -- Chapter 8. In situ detection of miRNAs in senescent cells in archival material -- Chapter 9. Novel probes and carriers to target senescent cells -- Chapter 10. Potential applications of aptamers for targeting senescent cells -- Chapter 11. Mitochondria: potential targets for interventions to counteract senescence.

This book offers comprehensive information on the new and rapidly evolving science of identifying and targeting senescent cells, and on the exciting prospect of new diagnostic and therapeutic opportunities for stopping, and even reversing, the progression of disease and the deterioration of the human body due to ageing. According to recent United Nations data, by 2050 one in six people worldwide will be older than age 65, with peaks rising to one in four people in Europe and North America. Remarkably, the number of persons aged 80 years or older is expected to triple, from 143 million in 2019 to 426 million in 2050. First documented in the 1960s, the concept of cellular senescence as an underlying cause of ageing has been established in the course of the last decade. Using genetically engineered mouse models, researchers have demonstrated that the selective elimination of senescent cells can block and even reverse a number of age-related dysfunctions and pathologies, promoting both better health and longer life in the elderly. These include cardiovascular diseases; neurological disorders; type 1 and type 2 diabetes; inflammatory diseases; fibrosis; geriatric syndromes; chronic diseases resulting in organ dysfunction; the integrity of the musculoskeletal system; and cancer. Some senolytic agents have already progressed into trials. These include UBX0101 for the treatment of osteoarthritis (now in phase II), a cocktail of dasatinib and quercetin for the management of idiopathic pulmonary fibrosis and chronic kidney disease, and ABT-263 in combination with senescence-inducing chemotherapies for the treatment of advanced solid tumours. In addition, the book discusses pathways to early phase clinical trials and translational approaches in medicine and ageing, highlighting new opportunities as well as current limitations, challenges and alternatives. Given its scope, it will benefit a broad audience of advanced educators, researchers, graduate students and practitioners.

ISBN: 9783030449032

Standard No.: 10.1007/978-3-030-44903-2doiSubjects--Topical Terms:

835004
Cells
--Aging.

LC Class. No.: QH608 / .S466 2020

Dewey Class. No.: 571.8

Senolytics in disease, ageing and longevity
LDR:04115nmm a2200337 a 4500 001 2217487
003 DE-He213
005 20200810152302.0
006 m d
007 cr nn 008maaau
008 201120s2020 sz s 0 eng d
020 $a 9783030449032 $q (electronic bk.)
020 $a 9783030449025 $q (paper)
024 7 $a 10.1007/978-3-030-44903-2 $2 doi
035 $a 978-3-030-44903-2
040 $a GP $c GP
041 0 $a eng
050 4 $a QH608 $b .S466 2020
072 7 $a PSC $2 bicssc
072 7 $a SCI072000 $2 bisacsh
072 7 $a PSC $2 thema
082 0 4 $a 571.8 $2 23
090 $a QH608 $b .S478 2020
245 0 0 $a Senolytics in disease, ageing and longevity $h [electronic resource] / $c edited by Daniel Munoz-Espin, Marco Demaria.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2020.
300 $a x, 222 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Healthy ageing and longevity, $x 2199-9007 ; $v v.11
505 0 $a Part I: Origins and Development of Senotherapies -- Chapter 1. Senolytic drug development -- Chapter 2. Discovery of Senolytics and the pathway to early phase clinical trials -- Part II: The Impact of Senotherapies: from Regeneration to Aging -- Chapter 3. Interconnection between cellular senescence, regeneration and ageing in salamanders -- Chapter 4. Senolytics target senescent cells and improve aging and age-related diseases -- Chapter 5. Senotherapy of cancer -- Part III: Understanding and Targeting the Senescent Surfaceome -- Chapter 6. Targeted senolytic strategies based on the senescent surfaceome -- Chapter 7. Senolysis and senostasis through the plasma membrane -- Part IV: Novel Senescence-Associated Markers and Targets -- Chapter 8. In situ detection of miRNAs in senescent cells in archival material -- Chapter 9. Novel probes and carriers to target senescent cells -- Chapter 10. Potential applications of aptamers for targeting senescent cells -- Chapter 11. Mitochondria: potential targets for interventions to counteract senescence.
520 $a This book offers comprehensive information on the new and rapidly evolving science of identifying and targeting senescent cells, and on the exciting prospect of new diagnostic and therapeutic opportunities for stopping, and even reversing, the progression of disease and the deterioration of the human body due to ageing. According to recent United Nations data, by 2050 one in six people worldwide will be older than age 65, with peaks rising to one in four people in Europe and North America. Remarkably, the number of persons aged 80 years or older is expected to triple, from 143 million in 2019 to 426 million in 2050. First documented in the 1960s, the concept of cellular senescence as an underlying cause of ageing has been established in the course of the last decade. Using genetically engineered mouse models, researchers have demonstrated that the selective elimination of senescent cells can block and even reverse a number of age-related dysfunctions and pathologies, promoting both better health and longer life in the elderly. These include cardiovascular diseases; neurological disorders; type 1 and type 2 diabetes; inflammatory diseases; fibrosis; geriatric syndromes; chronic diseases resulting in organ dysfunction; the integrity of the musculoskeletal system; and cancer. Some senolytic agents have already progressed into trials. These include UBX0101 for the treatment of osteoarthritis (now in phase II), a cocktail of dasatinib and quercetin for the management of idiopathic pulmonary fibrosis and chronic kidney disease, and ABT-263 in combination with senescence-inducing chemotherapies for the treatment of advanced solid tumours. In addition, the book discusses pathways to early phase clinical trials and translational approaches in medicine and ageing, highlighting new opportunities as well as current limitations, challenges and alternatives. Given its scope, it will benefit a broad audience of advanced educators, researchers, graduate students and practitioners.
650 0 $a Cells $x Aging. $3 835004
650 1 4 $a Biogerontology. $3 3413932
650 2 4 $a Regenerative Medicine/Tissue Engineering. $3 2055677
650 2 4 $a Animal Models. $3 1001014
650 2 4 $a Molecular Medicine. $3 890952
700 1 $a Munoz-Espin, Daniel. $3 3450733
700 1 $a Demaria, Marco. $3 3450734
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a Healthy ageing and longevity ; $v v.11. $3 3450735
856 4 0 $u https://doi.org/10.1007/978-3-030-44903-2
950 $a Biomedical and Life Sciences (Springer-11642)